Trials / Completed
CompletedNCT04023877
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to achieve mass balance recovery of \[14C\]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2027 | E2027 oral capsule. |
Timeline
- Start date
- 2019-07-18
- Primary completion
- 2019-10-11
- Completion
- 2019-10-11
- First posted
- 2019-07-18
- Last updated
- 2019-12-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04023877. Inclusion in this directory is not an endorsement.